US · Healthcare · Medical Devices
EPS came in at 1.45 against a street estimate of 1.39 — a beat of 4.3%.
Analysts rate Medtronic PLC a buy (17 buy, 13 hold, 2 sell out of 32) with an average price target of $104.76.
CONFIDENT MDT delivered strong Q1 FY27 with 13.7% organic growth and $1.45 EPS, raising full-year guidance to 7.25-7.75% revenue growth and $5.94-$6.00 EPS. CRM, CST, and Surgical all performed well; CAS grew 88% and surpassed $2B revenue milestone. Q1 FY27 Growth was broad-based geographically with nearly 16% U.S. growth and 12% international growth, demonstrating consistent execution across markets. Bank of America's Travis Steed pressed on base business acceleration ex-CAS and Cornerstone deal structure timing. Management emphasized breadth of performance across multiple growth drivers (Altaviva, Ardian, Hugo, Stealth AXiS) and noted Cornerstone expansion supports global robotics ecosystem, though deal commercial timing details deferred. 2026-09-01…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.84% |
| Vanguard Capital Management, LLC | 6.51% |
| State Street Corp | 4.82% |
| JPMorgan Chase & Co | 3.98% |
| Vanguard Portfolio Management, LLC | 2.61% |
| Geode Capital Management, LLC | 2.25% |
| Arnhold & S. Bleichroeder Advisers, LLC | 2.15% |
| Bank of America Corp | 2.03% |
| Document | Date |
|---|---|
| Quarterly report · Q1 FY2027 MEDTRONIC PLC – Q1 FY2027 (QUARTER ENDED JULY 31, 2026) SUMMARY --- HEADLINE NUMBERS • Net sales: $9,756 million (Q1 FY2027) vs. $8,578 million (Q1 | 2026-09-03 |
| Results announced · Q2 FY2027 MEDTRONIC PLC – Q1 FY2027 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 FY27 revenue: $9.756 billion, up 13.7% reported and 13.7% organic (roughly 200 basi | 2026-09-01 |
| Proxy statement · Q2 FY2027 MEDTRONIC PLC PROXY STATEMENT SUMMARY (FY2026) --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 12 director nominees for one-year terms (sep | 2026-08-17 |
| Annual report FY2026 MEDTRONIC PLC - FORM 10-K SUMMARY (FISCAL YEAR ENDED APRIL 24, 2026) HEADLINE NUMBERS • Market capitalization: Approximately $120.1 billion as of Oc | 2026-06-18 |
| Results announced · Q1 FY2027 MEDTRONIC PLC – FY2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 Revenue: $9.8 billion, up 9.9% reported / 6.6% organic • Q4 Non-GAAP Diluted EPS: $1.5 | 2026-06-03 |
| Board / officer change · Q1 FY2027 MEDTRONIC PLC - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Brett Wall departed as Executive Vice President and President, Neuroscience Portfol | 2026-05-18 |
| Reg FD disclosure · Q4 FY2026 MEDTRONIC PLC - FORM 8-K SUMMARY HEADLINE NUMBERS • Date of incident disclosure: April 24, 2026 • Company assessment: No material impact expected on | 2026-04-27 |
| Quarterly report · Q3 FY2026 MEDTRONIC PLC – Q3 2026 10-Q SUMMARY HEADLINE NUMBERS • Q3 Net Sales: $9,017 million (up 8.7% vs. Q3 2025: $8,292 million) • Nine-Month Net Sales: $ | 2026-02-24 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.72 / share ex-date Sep 25, 2026 · pay Oct 16, 2026 | 2026-09-25 |
| Dividend | $0.72 / share ex-date Jun 26, 2026 · pay Jul 17, 2026 | 2026-06-26 |
| Dividend | $0.71 / share ex-date Mar 27, 2026 · pay Apr 17, 2026 | 2026-03-27 |
| Dividend | $0.71 / share ex-date Dec 26, 2025 · pay Jan 16, 2026 | 2025-12-26 |
| Dividend | $0.71 / share ex-date Sep 26, 2025 · pay Oct 17, 2025 | 2025-09-26 |
| Announcement | Date |
|---|---|
| Fiscal 2026 non-GAAP EPS guidance lowered due to MiniMed-related impacts Medtronic announced that the FDA cleared MiniMed Flex, a smartphone-controlled insulin pump, several months ahead of schedule. While this product approval is positive, the announcement inclu | 2026-03-24 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Medtronic PLC — free to start.
Google PlayApp StoreData updated 2026-09-18.